News und Analysen

AbbVie (NYSE: ABBV) is an investment that is full of contradictions. It has a strong pharmaceutical business, but the third quarter of 2025 was terrible on the earnings front. It has an attractive

Is the S&P 500 due for a crash next year? That's a big question on the minds of many investors these days. Concerns about bubbles in tech and overall high valuations for the stock market have many

Investing in up-and-coming growth stocks can involve risk, but doing so can also result in tremendous returns if things go well. It all comes down to taking calculated risks and investing in stocks

Pfizer (NYSE: PFE) and Eli Lilly (NYSE: LLY) are two prominent names in healthcare that have focused on innovation and growing their respective businesses for decades. But in recent years, it's been

In today's video, I discuss recent updates affecting Advanced Micro Devices (NASDAQ: AMD) and other AI stocks. To learn more, check out the short video, consider subscribing, and click the special

No one knows how the stock market will unfold in 2026. Perhaps broader equities will experience significant volatility but perform well by the end of the year, just as they seem to be doing in 2025

While the pre-holiday season isn't usually a busy time for dividend raises, investors can usually expect a few companies to end the year on a high note by declaring one.

Sure enough, in the fading

Stock investors have many options to choose among, of course. These include individual equities, exchange-traded funds (ETFs), and mutual funds. But if I had to pick just one stock, I'd invest in

Nvidia (NASDAQ: NVDA) has been the "go-to" source for artificial intelligence (AI) chips since the start of the AI boom, and this is thanks to two things: the company's first-to-market advantage and

Pfizer (NYSE:PFE), which develops and sells biopharmaceutical products worldwide, closed today's session (Dec. 16) at $25.53, down 3.41%. Trading volume reached 108.1 million shares, almost 60%

Upstart biotech company Viking Therapeutics (NASDAQ: VKTX) is a potential takeover candidate in 2026. That's not a reason to buy the stock in itself, but does highlight the potential value in its

Investing in relatively small, unprofitable companies has advantages and drawbacks. On the one hand, these stocks tend to have explosive growth potential, much more so than most of their larger

A volatile trading environment and high inflation should not deter investors from the stock market. These challenges will eventually subside, and equities have performed well over the long term

After trailing broader equities over the past few years, will the healthcare sector finally bounce back in 2026? It's hard to predict those things.

No matter what happens to the industry, though

Several headwinds have pushed Regeneron's (NASDAQ: REGN) shares lower over the past year and a half. However, the company is bouncing back and has performed well in recent months. What's more, there

Telemedicine leader Teladoc Health (NYSE: TDOC) has been struggling for several years. The company's services are no longer experiencing the kind of demand they did during the pandemic years

Kevin P. Knight, Executive Chairman of Knight-Swift Transportation Holdings (NYSE:KNX), reported the indirect open-market sale of 35,000 shares for a transaction value of ~$1.8 million on Dec. 9

Healthcare stocks as a group have not performed on par with broader equities this year. However, that doesn't mean investors should avoid the sector altogether. Many healthcare companies appear to

Looking for great stocks to be had at a bargain? Even though broader equities have performed well this year, there are companies, particularly in sectors that haven't kept up with the rest of the

It now seems so long ago that Pfizer (NYSE: PFE) became the first company in the biopharmaceutical industry to generate over $100 billion in annual sales. The drugmaker achieved this milestone

Even very well-run companies will eventually fall upon hard times. That's the backstory you need to keep in mind when you examine Bristol Myers Squibb (NYSE: BMY) and Pfizer (NYSE: PFE). Here's why

Two pieces of encouraging news from Voyager Technologies (NYSE: VOYG) over the last several days have been propelling the company's shares higher. According to data compiled by S&P Global Market

Novavax (NASDAQ: NVAX) was once a leading contender to dominate the coronavirus vaccine market. The company faced several challenges, however, and although it successfully launched its vaccine

AbbVie (NYSE: ABBV), a pharmaceutical leader, has faced some challenges over the past three years. The company is managing some patent cliffs and clinical setbacks that worried investors and dinged